Motus GI appoints James J. Martin as CFO
Mr. Martin has nearly 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded medical device companies.
Most recently, Mr. Martin was the Chief Financial Officer of VBI Vaccines, Inc. (formerly SciVac Therapeutics, Inc.), a dual listed Canadian TSX and NASDAQ commercial vaccine company, where he led the company in the successful completion of a merger in July 2015 and an acquisition in May 2016.
Since 2010, he has also served as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc., a company marketing non-invasive medical devices.
From 2014 to 2015, he served as Chief Financial Officer of the NASDAQ listed Vapor Corp, Inc. after serving as Chief Financial Officer of NYSE listed TransEnterix, Inc. from 2010 to 2013.
Earlier in his career, Mr. Martin held finance positions at Aero Pharmaceuticals, AAR Aircraft Services and Systems Products International. He was also an Operations Specialist with the U.S. Navy from 1985 to 1990.
He holds an undergraduate degree in business administration and an MBA from Barry University in Miami and is a Certified Public Accountant. ■
LATEST MOVES FROM Israel
- Teva appoints Kåre Schultz as CEO
- Immune Pharma appoints Tony Fiorino as COO
- Enzymotec appoints Dror Israel as CFO
- Intec Pharma appoints Jeffrey A. Meckler as CEO
- Foamix Pharmaceuticals names David Domzalski as CEO
More inside POST
Kellogg to buy Rxbar for $600 million Companies